BioLineRx (BLRX) Projected to Post Quarterly Earnings on Tuesday

BioLineRx (NASDAQ:BLRX) is projected to announce its earnings results before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($4.20) per share and revenue of $7.72 million for the quarter.

BioLineRx Stock Up 4.7 %

BLRX stock opened at $3.58 on Monday. The company has a current ratio of 1.52, a quick ratio of 1.37 and a debt-to-equity ratio of 2.11. The firm has a 50 day simple moving average of $3.69 and a 200-day simple moving average of $11.69. The company has a market capitalization of $11.92 million, a P/E ratio of -0.41 and a beta of 1.39. BioLineRx has a twelve month low of $2.88 and a twelve month high of $54.00.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BLRX. HC Wainwright dropped their target price on shares of BioLineRx from $840.00 to $360.00 and set a “buy” rating for the company in a research report on Monday, November 25th. StockNews.com downgraded BioLineRx from a “hold” rating to a “sell” rating in a research note on Tuesday, March 18th.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.